PhRMA: New report shows nearly 260 vaccines in development, including dozens for COVID-19

Milestones :: Perspectives :: Research


PhRMA: New report shows nearly 260 vaccines in development, including dozens for COVID-19
Andrew Powaleny | April 23, 2020
…Today, biopharmaceutical companies are working with stakeholders across the research and development (R&D) ecosystem to develop new ways of preventing and treating illnesses with innovative vaccines. According to a new report, there are currently 258 vaccines in development for the treatment or prevention of disease.

Among the vaccines in development are:
:: 108 vaccines for cancer, including a therapeutic vaccine for non-small cell lung cancer, which uses messenger RNA to mobilize the patient’s own immune system to fight the tumor(s)
:: 125 vaccines for infectious diseases, including a vaccine designed to prevent HIV infection by teaching a patient’s immune system to recognize and effectively fight the virus
:: 14 vaccines for allergies, including vaccines that target peanut allergies
:: 2 vaccines for Alzheimer’s disease, including one therapeutic vaccine that targets amyloid beta protein, which is linked to the development of the neurological disorder

Additionally, numerous different types of potential vaccines are in development that target COVID-19. Researchers are working around the clock amidst the global pandemic to develop safe, effective and affordable vaccines that will prevent both individual infection and the continued spread of the virus. As of April 15, 2020:
:: There are more than 70 vaccines for COVID-19 in the global research pipeline.
:: And six vaccines for COVID-19 have entered human clinical trials with many planning to begin human trials this year…